Sarepta Therapeutics Inc (NASDAQ:SRPT)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Results 1 - 20 of 57 : 1 2 3 Next »

Recs

1
Member Avatar Camilo99 (< 20) Submitted: 10/21/2014 3:06:16 AM : Outperform Start Price: $22.59 SRPT Score: +0.54

The media is starting to cause a Ebola histerya that will give a push to stocks related to it.

Recs

1
Member Avatar deacon (< 20) Submitted: 10/16/2014 6:50:24 PM : Outperform Start Price: $24.74 SRPT Score: -10.33

EBOLA treatment drug advanced to primate testing showing no adverse side effects

Recs

0
Member Avatar Sparticus501 (20.43) Submitted: 10/10/2014 9:35:55 PM : Outperform Start Price: $18.75 SRPT Score: +20.53

Short term burst in stock price due to Ebola panic. This stock should go higher over the next year.

Recs

1
Member Avatar jbwheels69 (48.91) Submitted: 10/1/2014 3:09:23 PM : Outperform Start Price: $21.93 SRPT Score: +4.71

Decent entry point

Recs

1
Member Avatar newsie111 (< 20) Submitted: 9/4/2014 7:20:19 PM : Outperform Start Price: $22.76 SRPT Score: +3.69

FDA will green light its Duchenne Muscular Dystrophy drug in coming months

Recs

1
Member Avatar trizoll (63.71) Submitted: 7/16/2014 9:55:29 PM : Outperform Start Price: $20.50 SRPT Score: +13.62

Will rebound from 144 week study results. The benefit is really compared to the placebo. There is a huge benefit there. I think the drug will get approved in 2015.

Recs

0
Member Avatar MKArch (99.69) Submitted: 7/2/2014 2:30:14 AM : Outperform Start Price: $30.14 SRPT Score: -22.48

Following a guy on Yahoo Finance that sounds like he knows what he's talking about. Yep really that's it. O.K. he made an interesting argument for HART a similar company I have done a little investigating into so I'm taking a flier that he understands this one enough to put it into my CAPS portfolio. Potential multi-bagger a few years out, we shall see.

Recs

0
Member Avatar Redbeagle (39.65) Submitted: 3/17/2014 12:07:55 PM : Outperform Start Price: $27.23 SRPT Score: -20.04

Good drug pipeline

Recs

0
Member Avatar mulledover (82.00) Submitted: 3/15/2014 11:59:06 AM : Outperform Start Price: $27.38 SRPT Score: -20.88

Phase ii results in duchenne prove their capabilities although this will likely take 2-3 years for further trials. However it's their RNA platform that makes this an interesting company for antiviral drugs for infectious diseases

Recs

0
Member Avatar manirg (76.56) Submitted: 1/27/2014 12:41:25 PM : Outperform Start Price: $23.28 SRPT Score: -10.73

Its drug is only the treatment for DMD. FDA is likely to approve it sooner or later. Hugh long term potential.

Recs

0
Member Avatar baileysmom (< 20) Submitted: 1/26/2014 8:08:50 PM : Outperform Start Price: $24.65 SRPT Score: -15.39

The only game in town when it comes to Duchenne Muscular Dystophy.

Recs

0
Member Avatar ferrariedgardo (32.26) Submitted: 1/16/2014 6:57:41 PM : Outperform Start Price: $27.37 SRPT Score: -21.70

DMD trial going well

Recs

1
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $32.49 SRPT Score: +46.13

Short. Biopharma. Sells more stock than has revenues. Revs declining too.

Recs

3
Member Avatar EllenBrandtPhD (< 20) Submitted: 8/17/2013 2:58:48 PM : Outperform Start Price: $32.59 SRPT Score: -47.14

This is a terrifying stock, because its moves tend to be so dramatic.

If you calculate its next Big Turn correctly, either on the downside or the upside, you can make out like a bandit.

The technical picture could hardly have been worse prior to Friday's big up day, but there were many hints something was brewing. It came in the form of a key analyst upgrade and a new Propaganda push beginning Friday.

I think it may continue and that the next Big Turn - Propaganda leading Technicals - may be here.

Recs

3
Member Avatar TMFBiologyFool (96.65) Submitted: 7/24/2013 4:31:02 PM : Outperform Start Price: $37.00 SRPT Score: -53.61

Over punished on delay of FDA decision about surrogate endpoint. Should trend back up as we get closer to FDA decision.

Recs

1
Member Avatar Momentum21 (80.85) Submitted: 7/24/2013 11:34:22 AM : Outperform Start Price: $39.73 SRPT Score: -57.38

sold a little off at 46, back in at 39.99. Too many seem to like this ticker for my taste but that's OK...

https://twitter.com/Momentum21Fund

Recs

0
Member Avatar SUPERSTOCKS007 (< 20) Submitted: 5/27/2013 1:39:26 PM : Outperform Start Price: $38.75 SRPT Score: -57.24

right drug at the right time

Recs

0
Member Avatar IBDContrarian (20.08) Submitted: 4/6/2013 1:51:34 PM : Underperform Start Price: $37.06 SRPT Score: +63.37

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 99 EB NO EARN

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:34:43 PM : Outperform Start Price: $30.37 SRPT Score: -52.58

SRPT is about to breakout huge to the upside on accelerated approval status by the FDA. Initial projections of a patient population of only 300 is vastly underestimated as it is closer to 6,000.

Recs

0
Member Avatar ravikaza2 (< 20) Submitted: 3/3/2013 7:57:45 PM : Outperform Start Price: $30.37 SRPT Score: -52.58

Only new treatment for DMD

Results 1 - 20 of 57 : 1 2 3 Next »

Featured Broker Partners


Advertisement